We show Protein Kinase C-zeta variant "b" (PKC-ζ -b ) to be a novel predictive biomarker for survival from prostate cancer (p < 0.001). We also confirm that transcription of the PRKC-ζ gene is crucial to the malignant phenotype of human prostate cancer. Following siRNA silencing of PRKC-ζ in PC3-M prostate cancer cells, stable transfectant cell-line si-PRKC-ζ -b-PC3-M T1-6 is phenotypically nonmalignant in-vitro and in-vivo. Genome-wide expression analysis identified 373 genes to be differentially expressed in the knockdown cells and four key gene-networks to be significantly perturbed during phenotype modulation. Functional interconnection between some of the modulated genes is revealed, although these may be within different regulatory pathways, emphasizing the complexity of their mutual interdependence. Genes with altered expression following PRKC-ζ knockdown include HSPB1, RAD51 and ID1 that we have previously described to be critically important in prostatic malignancy. Since expression of PRKC-ζ -b is functionally involved in promoting the malignant phenotype, we propose PKC-ζ -b as a novel and biologically-relevant target for therapeutic intervention in prostate cancer.
Introduction
Prostate cancer is the second most common cancer to affect men worldwide. In the USA, in 2008, 186,320 new cases of prostate cancer and 28,660 deaths from this disease were reported 1 from relative indolence to highly aggressive with progression occurring rapidly. Hence, there is an urgent requirement to develop reliable biomarkers that accurately stratify prostate cancer at diagnosis and segregate men with aggressive cancers requiring urgent treatment from those who may be managed conservatively 6 . While extent of disease is more useful than clinical stage at diagnosis, and retains a low level of significance in multivariate analysis, neither parameters is of clinical utility being significantly inferior to Gleason score or PSA 7 .
A potential functional relationship between PKC-ζ, encoded by the gene PRKCZ located on chromosome 1 at p36.33-p36.2, and prostate cancer was first suggested by our study that showed expression of PKC-ζ to be enhanced in prostatic malignancy when compared to morphologically nonmalignant prostatic epithelium 8 . These findings were subsequently validated by other studies in cancers of breast 9 , lung 10, 11 and pancreas 12, 13 . Reduction in PKC-ζ inhibits cell migration and invasion, confirming the protein to be functionally important to the malignant phenotype 10, 11 . While our original data suggested that strong PKC-ζ expression might identify a subset of aggressive prostate cancers, the cohort was heterogeneous and too few to provide reliable statistics. This study has assessed PKC-ζ expression in the largest group of well-characterized and conservatively managed patients yet to be assembled world-wide 7 .
Protein Kinase C (PKC) isoenzymes together comprise a complex super-family of 14 serinethreonine kinases characterized by structural similarities in certain gene-elements and functional peptide domains 14 . Broadly considered as regulators of cellular homeostasis and behavioral phenotype, these enzymes are increasingly identified to be polyfunctional. The genes for all of these enzymes characteristically encode multiple splice variants that are differentially expressed between tissues in a wide range of animal species during tissue morphogenesis 15 , especially between malignant tissues and their benign histogenic counterparts 8, 12 . Different PKC isoforms exhibit opposing cell-regulatory actions 16, 17 . In prostate cancer, preliminary studies demonstrated only the expression of PRKC-ζ isoform "b" in PC3-M cells 18 .
Examples of genes selectively modulated in prostate cancer are now relatively frequent 19 .
Some of these, either up-or down-regulated, have been proposed as robust biomarkers able to segregate different cancer phenotypes according to parameters that include behavior and response to therapy 20 .
While altered expression does not confirm, ipso facto, a functional role in malignancy, genes that we have demonstrated to be functionally relevant to the aggressive phenotype of prostate cancer include cFABP 21 , RPL19 22 , ID1 23 , RAD51 24 and HSPB1 25 . Studies reported from this laboratory 26 and elsewhere 27, 28 have also established a functional relationship between PKC-ζ voltage-gated ion channels 16 and the invasive phenotype of prostate cancer cells 29 . Similarly, the behavior of malignant cells is influenced by expression of cell-surface complex glycoconjugates, particularly sialic acids 30, 31 .
Therefore, the objectives of this study were: (i) to confirm the predictive biomarker potential of PKC-ζ -b protein expression in a large cohort of untreated human prostate cancers (ii) to test the hypothesis that translation and expression of PRKC-ζ is functionally important in promoting and/or maintaining the aggressive phenotype of prostate cancer, and hence a potential drug target, and (iii) to elucidate the genes and their associated networks modulated by PRKC-ζ.
Results

PKC-ζ protein expression in prostate tissues and clinical correlations
Information on PKC-ζ staining intensity was available for 2879 cores from 783 patients. Morphological appearances of the distribution of cytoplasmic PKC-ζ expression ranged from benign through malignant ( Figure 1 ). For the 667 patients with positive staining (i.e. ≥ 1), their demographics and tumor characteristics are presented in Table 1 . Figures 2a & 2b show the distribution of PKC-ζ staining and intensity in the 901 morphologically unremarkable cores (10%), 798 hyperplasic cores (36%), 38 PIN cores (76%) and 1142 cancer cores (90%) analyzed in the arrays. The relationship of PKC-ζ expression (binary variables: staining intensity ≤ 2 and = 3) with demographics and tumor characteristics is presented in Table 2 . At both levels, PKC-ζ expression was associated with Gleason score (p < 0.001),
clinical stage (p < 0.001) and amount of cancer in each specimen (p < 0.001). No association was found with age or baseline PSA. At high intensity (i.e. = 3+), expression of PKC-ζ was associated with worse survival from prostate cancer ( Figure 2c ) and poor overall survival ( Figure 2d ). Univariate Cox model analysis ( multivariate of these models, there was no association with overall survival. We conclude from these analyses that PKC-ζ expression is highly correlated with existing prognostic markers including Gleason score and clinical stage but does not, alone, represent an independent prognostic marker. However, within poor-prognosis prostate cancers, it might define a phenotypic subset amenable to therapeutic manipulation of PRKC-ζ -b .
PRKC-ζ -b mRNA expression
Previous Western blotting studies indicated that PRKC-ζ -b was the only isoform expressed in prostate cancer cell-lines and most strongly expressed in PC3-M cells (Figure 3a ) that we selected for use as our 
Glycoconjugate expression
Western blotting to detect sialylated glycoproteins revealed subtle differences in binding-patterns between the control and knockdown cells, particularly gain of Neu5Acα2,6Gal-structures identified by Sambuccus (Figure 6b ) indicating significant changes to specific proteins. These might be caused by Table   1 ) and 157 down-regulated (Supplemental Table 2 ). Frequently, multiple sequences for an individual gene were ranked in close proximity, confirming the quality of this dataset. 
Ion channel genes modulated in si-PRKC-ζ -b -PC3-M T1-6 cells
The oligonucleotide expression arrays were interrogated to determine whether genes encoding ion channels were modulated following PRKC-ζ -b knockdown. Two groups affected were voltage-gated K + channel genes KCNN4 (up-regulated ~2.4-fold, p < 0.005), KCNK10 (down-regulated ~1.8-fold, p < 0.01) and KCNMA1 (down-regulated ~1.5-fold, p < 0.01) together with the Na + /K + transporting
ATPase's β1and β3 polypeptide genes ATP1B1 (down-regulated ~1.6-fold, p < 0.01) and ATP1B3
(down-regulated ~1.5-fold, p < 0.01). Although the specific functions of these channels is complex, they are all involved in cellular homeostasis of various types, including maintenance of cell polarity.
These expression array data reveal a possible functional interaction between the glycosyltransferase genes and the ion channel genes such that they together contribute to modulating the parental PC3-M cells from a malignant towards a benign phenotype.
Discussion
At diagnosis, PKC-ζ protein expression is confirmed as a powerful predictive biomarker for survival from prostate cancer (p < 0.001) and for overall survival (p < 0.001 These RNAi studies, the first to be reported in human prostate cancer (Supplemental . These data together with the finding that enhanced KCNMA1 expression is functionally involved in breast cancer invasion and metastasis to brain 38 , not only exemplify the biological relevance of these channels but supports a reciprocal interaction between ion channels, alterations in glycosyltransferase expression and malignancy. The cellular distribution and role of the ion channels modulated following PRKC-ζ -bknockdown is directly dependent upon their appropriate patterns of N-linked glycosylation such that any alteration inhibits their functionality causing impaired cell polarization 39, 40 . Similarly, changes in ion channels disturb intracellular pH gradients with the consequence that certain proteins undergo alternative patterns of glycosylation, as evidenced by the glycoconjugate expression data ( Figure 6 ) potentially resulting in their modulated distribution and/or functionality 41 .
The importance of PRKC-ζ -b in prostate cancer cell motility is supported by reduced colony formation in soft agar and impaired tumor cell invasion through a collagen matrix (Figure 4c-f) following gene knock-down. A similar role for PKC-ζ has been proposed in pancreatic cancer cells 13 after inhibition of PRKC-ζ either chemically 42 or genetically 43 . To develop the mechanical forces necessary for cell migration, as well as interacting with actin 44, 45 , direct phosphorylation of myosin II-B protein by PKC-ζ occurs in TSU-pr1 prostatic adenocarcinoma cells in an EGF-dependant manner when complexed with p21-activated kinase-1 (PAK-1). In this pathway, PKC-ζ is phosphorylated and activated by PAK-1, promoting phosphorylation of myosin II-B 46 .
In addition to a functionally-competent locomotor assembly, maintenance of cell polarity and loss of cell-cell adhesion are essential for cell migration 47 . For a cell to migrate, generation of a forward-rear polarity axis occurs principally through the PAR-PKC-ζ system 48 Our current studies clearly demonstrate enhanced site-specific phosphorylation of Hsp-27 Ser 82 in si- Identification of gene interaction networks is a powerful approach to segregating prostatic malignancies into biologically-defined groups amenable to different types of therapeutic intervention 57, 58 . However, there is a caveat that application of the types of data reported herein depends upon the integrity and expression of key genes that determine the genotype of each individual prostatic malignancy. In PC3-M prostate cancer cells, the gene TP53 is non-mutated, characteristic of approximately 60% of primary prostate cancers, supporting the proposition that down-regulation of PRKC-ζ would be effective in this group. Such cells are potentially able to regulate DNA replication through GINS complex members 59 , an essential component of the human replisome. In the current study, down-regulation of GINS2 (~7-fold, p < 0.05) was associated with a concomitant reduction in PCNA (~8-fold, p < 0.01), CDC2 (~7-fold, p < 0.05), CCDC74B (~8-fold, p < 0.01) and CDC45L (~10-fold, p < 0.05) indicating altered regulation of mitosis during initiation as well as S-phase and G 2 -M progression 60 to occur as a consequence of PRKC-ζ -b knockdown. This method has revealed the members of several different networks to be reduced following knockdown of PRKC-ζ -b (Supplemental Table 2 ). These included the gene ID1 (~8-fold, p < 0.05) and RAD51 (~10-fold, p < 0.01) that we have already shown to be associated (p < 0.001) with aggressive prostate cancer 23, 24 . In this study, members of the NFκB pathway were principally reduced, particularly NFKBIA (~10-fold, p < 0.01). The NFκB complex is recognized to be inhibited by IκB proteins (NFκBIA or NFκBIB) that trap and inactivate NFκB 61 . Phosphorylation of serine residues within the IκB proteins by a range of kinases marks them for destruction following ubiquitination, thereby allowing activation of the NFκB complex.
Simultaneous up-regulation of phosphoenolpyruvate carboxykinase 2 (PKC2, ~4-fold, p < 0.05, Supplemental Presently, the most effective agents are the PKC-β inhibitors briostatin-1 and enzastaurin, the latter being trialed against human lung cancer 66 while in human NSCLC, aurothiomalate and aurothioglucose are selective and effective inhibitors of PKC-ι, the homologue of PKC-ζ 67 . Recently, spheciosterol sulfates extracted from Philippine sponges 68 and a novel class of small molecules (the 3-hydroxy-2-(3-hydroxyphenyl)-4H-1-benzopyran-4-ones) have been described as isoform-selective PKC-ζ inhibitors 69 . Therapeutically employed for psychostimulant abuse, the potential value of these latter agents has yet to be assessed in treating epithelial malignancies. With reference to their inhibitory effects on prostate cancer metastases, bisphosphonates (e.g. pamidronate) specifically inhibit PKC-α and PKC-ζ, possibly through a network effect on urokinase-type plasminogen activator 70 . It is anticipated that the emerging PKC isoform-selectivity of new small molecule inhibitors 71 together with the identification of tissue-specific PKC variants 18, 72 will provide a high level of tumor-specificity for therapeutic intervention in the management of malignant diseases.
Herein, we provide robust evidence that PKC-ζ -is not only functionally involved in promoting and maintaining prostate cancer but that the gene PRKC-ζ -b is a biologically effective target for control of this malignancy. Furthermore, the consequences of reducing PKC-ζ through PRKC-ζ -b gene knockdown, particularly identification of other potential targets such as the voltage-gated K + channels 73 , allows development of a comprehensive therapeutic strategy based upon detailed knowledge of biological pathways active in subsets of human prostate cancer. Understanding the potential impact of such approaches is not possible without a robust and validated database of molecular interactions. For cancer therapeutics, there are two corollaries: First, is that mathematical modeling of genes expressed by an individual cancer will allow accurate prediction of susceptibilities and weaknesses that might be exploited to treat each malignant disease in a biologically-appropriate manner 74 . Second, is the concept of phenotypic modulation to treat cancers 75 . Through phenotypic modulation, prevention of metastases while maintaining the general health of a patient with early cancer would provide additional time to introduce second-line therapies to target specific networks such as NFκB 76, 77 in the knowledge that these would be biologically appropriate to accommodate the phenotypic changes induced in malignant cells by a first-line therapy.
Materials and Methods
Patient Cohort and Tissue Micro-Arrays (TMAs) for PKC-ζ analysis
The study analysed a panel of TMAs constructed from a retrospective cohort of >2000 men with prostate cancer assembled from the records held by UK cancer registries and managed only conservatively 7, 78 .
Ethical approval
National approval for the collection of the cohort was obtained from the Northern Multi-Research Ethics Committee followed by local ethics committee approval at each of the collaborating hospital
trusts. This work was approved by the Clinical Research and Ethics Committee at the Royal Marsden
Hospital and The Institute of Cancer Research.
PKC-ζ immunohistochemistry
Mouse monoclonal antibody sc-216 to PKC-ζ (Insight Biotechnology Ltd. Wembley, Middlesex, UK) recognizes a unique 20-peptide sequence located in the -COOH terminal domain of variant "b" (NM_002774) encoded by exon 90 (AceView nomenclature) of the PRKCZ gene 18 . TMA sections were processed, stained and analyzed 8, 25 .
Analysis of PKC-ζ expression
Specimens were considered positive only when at least 5% of the epithelial cells (either normal or malignant) unequivocally expressed PKC-ζ staining 79 . This cut-off was the same as that used to distinguish positive and negative immunohistochemical staining in our previous studies 8, 25 . Staining was assessed as negative, weakly positive or only focally positive (low-level expression), or strongly positive (high-level expression) and scored as 0, 1, 2 or 3, respectively.
Statistical analysis of TMA immunohistochemistry
The primary endpoint for this study was time to death from prostate cancer. Time to death from any cause was the secondary endpoint. Univariate and multivariate analysis were performed by proportional hazard (Cox) regression analysis 25, 80 . Correlation of PKC-ζ staining (3+ vs 2+ or less) with other known prognostic factors was done by 2-sample trend tests.
Cell lines
Human prostate cell-lines PNT-2 (benign) and PC3-M control (highly malignant) were grown as monolayer cultures in RPMI 1640 (Invitrogen, Paisley, UK) supplemented with 10% (v/v) foetal calf serum (FCS, Invitrogen), penicillin (1000units/ml), streptomycin (100μg/ml), and L-glutamine (2mM).
Media for the culture of all subsequent transfected cell-lines were also supplemented with 1µg/µl Geneticin (Sigma).
RNAi molecule designed to knock down PRKC-ζ -b
A unique 21nt sequence (GTGAGAGACATGTGTCGTCTT) located at the Database, GenBank, RefSeq and PDB confirmed this sequence to be contained within PRKCZ variants "a", "h", "l", "v-l" and "v-f" in addition to variant "b", the wild-type variant (NM_002774) recognized to occur in human prostate cancer. These are either not expressed in prostatic carcinoma cells PC3-M, Du145 or LNCaP or are truncated and considered to be functionally ineffective.
Top Strand:
Bottom Strand:
The default Ambion loop sequence, TTCAAGAGA, was used to complete the hairpin structure. The CMV-scramble-insert (1μg) using SiPORT XP-1 (3μl) reagent (Ambion, Warrington, UK) in 6-wellplates (35mm diameter). 24 hours after transfection, 500ng/ml of G418 was added to medium RPMI1640 for selection. After 9-10 days selection, individual colonies from single cells containing stable clones were isolated using ring cloning and transferred into 24-well plates with medium containing G418 at 500ng /ml.
RNA extraction and cDNA synthesis
Total RNA was extracted with RNeasy Mini Kits (Qiagen). Total RNA concentration was measured using a NanoDrop (Labtech, Ringmer, UK) and RNA integrity assessed with a 2100 Bioanalyser (Agilent, Santa Clare, USA). The RNA integrity number (RIN) for all RNA used exceeded 9.0. First strand cDNA was synthesized from 0.5µg total RNA using AffinityScript™ Multiple Temperature cDNA synthesis kits (Stratagene, La Jolla, USA) according to the manufacturer's protocol.
Quantitative Real-Time PCR (qPCR)
PRKC-ζ-b mRNA expression levels were quantified by qPCR and normalized relative to human β-actin mRNA expression. Primer sequences employed are shown in Table 4 . Reaction volumes were in 25 µl comprising 12.5 µl Stratagene's Brilliant® SYBR® Green Master Mix (2X), 0.5µM of both forward and reverse primers, 1µl cDNA and 11.5 µl water. Primers for qPCR were designed to span exon/exon boundaries within the mRNA to avoid amplification of genomic DNA.
Proliferation assay of controls and siRNA transfectants
An assay to identify the effect of PRKC-ζ -b suppression on cellular proliferation assessed cell-lines PNT-2 , PC3-M control , PC3-M scramble and two si-PRKC-ζ -b -PC3-M clones. Exponentially-growing cells were seeded in triplicate sets at a density of 1 x 10 3 cells/ml/well in 24 well plates. Over 6 days at 24 hour intervals, cell proliferation was calculated by measuring the increase in cell numbers in each replicate using a conventional MTT assay 81 .
Apoptotic properties of controls and siRNA transfectants
Apoptosis was quantified using flow cytometry. Cells were seeded at 2x10 5 cells/ml in 75cm 2 tissue culture flasks and the assay conducted during their linear growth-phase prior to reaching confluence.
Cells were harvested by trypsinization, washed twice with PBS and re-suspended in buffer from the BioVision Annexin V-FITC kit in a 5ml flow cytometry tube. AnnexinV-FITC (5µl) and propidium iodide (10ng in 5µl aqueous solution) were added and the tubes incubated for 10 minutes in darkness at 4°C. Quantitative analyses of apoptotic cell levels were performed using an Epics Flow Cytometer (Beckman Coulter). The procedure was performed three times using biological replicates.
Soft agar tumorgenicity assay
Cells were grown under standard environmental conditions as suspension cultures at a concentration of 2.5 x 10 3 cells/ml in 0.3% (w/v) agarose at 37ºC, 100% humidity and 5% CO 2 in air. After 3 weeks incubation, cell colonies were counted and photographed using a GelCount™ (Oxford Optronix, Oxford, UK) instrument. Any colonies of diameter <30µm or >100µm were excluded, the latter probably signifying that these were not derived from single cells.
In-vitro invasion
Invasiveness of the si-PRKC-ζ -b transfectants was assessed in-vitro 82 . At 24-hour intervals, following fixation and staining with Crystal Violet (Sigma-Aldrich, St Louis, USA), invasion was measured by counting the number of cells transmigrating the membrane to its under-surface.
In-vivo growth
Tumorigenicity and metastatic ability in-vivo were measured All tissues were processed, embedded in paraffin wax and histological sections cut at 4µm before staining with Gill's hematoxylin. All animal experiments were conducted under UKCCR guidelines.
Hsp-27 expression and phosphorylation status
Differential phosphorylation of regulatory protein Hsp-27 at Ser 
Glycoconjugate expression
To determine whether PRKC-ζ knockdown affected oligosaccharide profiles, lectin binding was performed using intact cells and their protein extracts. Cell blocks were prepared from cell-lines PNT-2,
85
. Sections cut at 5 μm were stained for Neu5Acα2→3Gal-and Neu5Acα2→6Gal-using the biotinylated lectins (Vector Laboratories, Peterborough, UK) from Sambucus nigra and Maackia amurensis respectively 86 . Negative controls included the absence of staining when the lectins were not included in the staining protocol and removal of sialic acids with subsequent abolition of staining following pre-treatment of the slides with neuraminidase 87 prior to incubation with either of these lectins. Lectin-binding was confirmed using avidin-fluorochrome conjugates visualized with an Olympus BX61 fluorescent microscope and x100
objective. To identify global changes in glycoprotein expression following siRNA knockdown of PRKC-ζ -b , Western blotting of cell lysates using each lectin was performed as described for the detection of Hsp-27 (above) with the exception that non-specific binding of protein to the PVDF membranes was blocked with BSA (1.5%, w/v) rather than milk. Before use, the optimal dilution of each lectin in PBS (100mM, pH 7.6) containing BSA (1.5%, w/v) was determined by titration against separated PC3-M control cell-lysates.
Gene microarray and expression analysis
The 
